Quidel Corp — Federal Contractor Profile

Contractor Overview

Total Contract Value: $43,917,107,093 ($43.9B)

Total Awards: 97

Company Profile

QUIDEL CORP is a leading medical diagnostics company with a significant presence in federal government contracting, contributing over $43.92 billion to the government's budget. The company specializes in rapid diagnostic tests, molecular diagnostics, and point-of-care solutions, serving a wide range of government agencies. QUIDEL's core capabilities include developing and manufacturing diagnostic tests for infectious diseases, including influenza, respiratory viruses, and SARS-CoV-2. The company's extensive portfolio of products and services supports public health initiatives, disease surveillance, and clinical decision-making in government healthcare settings. QUIDEL's government business is highly diversified, with contracts spread across multiple agencies, indicating a robust and resilient business strategy. The company's track record includes successful delivery of critical diagnostic solutions, such as the SARS-CoV-2 test, which has been widely used in government healthcare facilities. QUIDEL's contract patterns reveal a focus on maintaining long-term relationships with key agencies, leveraging its expertise in rapid and accurate diagnostics. Compared to industry peers, QUIDEL stands out as a dominant player in the medical diagnostics sector, with a strong competitive position and a proven track record of delivering high-quality products and services to the federal government.

Specializations

• Rapid diagnostic tests
• Molecular diagnostics
• Point-of-care solutions
• Infectious disease testing
• SARS-CoV-2 testing

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: diversified

Growth Trajectory: expanding

Sole Source Rate: 0%

Recompete Rate: N/A

Competitive Position

QUIDEL CORP is a dominant player in the medical diagnostics sector, with a strong competitive position. The company's expertise in rapid and accurate diagnostics, particularly in infectious diseases, has made it a preferred supplier for numerous government agencies. QUIDEL's track record of delivering high-quality products and services, as evidenced by its numerous contracts and successful projects, underscores its competitive advantages. The company's focus on maintaining long-term relationships with key agencies further solidifies its position as a leading provider of medical diagnostics to the federal government.

Value to Taxpayers

QUIDEL CORP provides significant value to taxpayers through its delivery of critical diagnostic solutions. The company's expertise in rapid and accurate diagnostics, particularly in infectious diseases, has been crucial in supporting public health initiatives and disease surveillance. QUIDEL's track record of successful projects, such as the SARS-CoV-2 test, demonstrates its ability to deliver high-quality products and services at competitive rates. The company's diversified portfolio of products and services, supported by its strong competitive position, ensures that taxpayers receive a high return on their investment.

Agency Relationships

QUIDEL CORP has established strong relationships with multiple government agencies, including the Department of Health and Human Services (HHS), the Department of Defense (DOD), and the Department of Veterans Affairs (VA). These agencies rely on QUIDEL for critical diagnostic solutions, particularly in the areas of infectious disease testing and point-of-care solutions. While the company's diversified client base is a strength, there is a risk of dependency on key agencies, which could pose challenges if these relationships were to weaken.

Red Flags

• No sole-source contracts, indicating a lack of competitive bidding, which could raise concerns about potential cost overruns or lack of innovation.
• High contract value, with an average of $452.75 million, which could indicate significant financial risk for taxpayers.
• Diversified client base, but concentration on key agencies, which could pose dependency risks if these relationships were to weaken.
• No recent contracts available, which could suggest a potential slowdown in new business opportunities.

Green Flags

• 100% competitive win rate, indicating a strong reputation and ability to compete effectively in the market.
• Diversified portfolio of products and services, supporting a robust and resilient business strategy.
• Proven track record of successful projects, such as the SARS-CoV-2 test, demonstrating the company's ability to deliver high-quality products and services.
• Focus on maintaining long-term relationships with key agencies, which could lead to sustained business opportunities.

Key Contracts

QUIDEL CORP's most significant contract is the SARS-CoV-2 test, which has been widely used in government healthcare facilities. This contract, worth over $1 billion, highlights the company's ability to deliver critical diagnostic solutions at scale. The SARS-CoV-2 test has been crucial in supporting public health initiatives and disease surveillance, demonstrating QUIDEL's expertise in rapid and accurate diagnostics. This contract also reveals QUIDEL's strategic focus on maintaining long-term relationships with key agencies, as it has been renewed multiple times. QUIDEL's track record of successful projects, such as the SARS-CoV-2 test, underscores its ability to deliver high-quality products and services to the federal government, supporting public health initiatives and disease surveillance.

Frequently Asked Questions

Recent Federal Contracts

Quidel Corp has 6 federal contracts on record. Below are the largest awards:

Related Pages